Industry / Germany
German Health Committee To Decide On Insulin Analogues
March 2006 | Company Finance AlertThe German federal healthcare committee - the GBA - is to decide next month whether expensive short-acting insulin products should be excluded from the reimbursement list.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
